AFP and hepatocellular carcinoma: Despite the disadvantage of low sensitivity, low specificity and limited accuracy in HCC early diagnosis, serum alpha-fetoprotein (AFP) has still been recommended as a biomarker to evaluate prognosis and monitor recurrence following treatment for HCC in clinical practice [9–12].